About Aspartate beta-hydroxylase domain-containing protein 2
Aspartate beta-hydroxylase domain-containing protein 2 (ASPHD2) is a protein
from Homo sapiens identified by UniProt accession
Q6ICH7, 369 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | Aspartate beta-hydroxylase domain-containing protein 2 |
| UniProt accession | Q6ICH7 |
| Gene | ASPHD2 |
| Organism | Homo sapiens |
| Length | 369 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (28)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- blood protein measurement · score 0.08
- neurofibrillary tangles measurement · score 0.05
- PHF-tau measurement · score 0.05
- Hepatitis · score 0.04
- mathematical ability · score 0.03
- cognitive function measurement · score 0.03
- diet measurement · score 0.03
- self reported educational attainment · score 0.02
- ependymoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6ICH7-F1 | alphafold | PREDICTED | 80.76 | — |
Amino-acid sequence (369 residues)
MVWAPLGPPR TDCLTLLHTP SKDSPKMSLE WLVAWSWSLD GLRDCIATGI QSVRDCDTTA VITVACLLVL FVWYCYHVGR EQPRPYVSVN SLMQAADANG LQNGYVYCQS PECVRCTHNE GLNQKLYHNL QEYAKRYSWS GMGRIHKGIR EQGRYLNSRP SIQKPEVFFL PDLPTTPYFS RDAQKHDVEV LERNFQTILC EFETLYKAFS NCSLPQGWKM NSTPSGEWFT FYLVNQGVCV PRNCRKCPRT YRLLGSLRTC IGNNVFGNAC ISVLSPGTVI TEHYGPTNIR IRCHLGLKTP NGCELVVGGE PQCWAEGRCL LFDDSFLHAA FHEGSAEDGP RVVFMVDLWH PNVAAAERQA LDFIFAPGR
Explore Aspartate beta-hydroxylase domain-containing protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets